Issue 3 - Jan 17, 2020
Issue 2 - Jan 10, 2020
  • Guest Editorial

    Immunotherapy, precision medicine in lung cancer drive sharp decline in cancer mortality overall

    As I look through just-published tables of age-adjusted cancer mortality, I recognize an unprecedented development:

    Immunotherapy is showing such a dramatic impact in the treatment of locally advanced and advanced non-small cell lung cancer that this effect elevates the statistics for all lung cancer and—this I find astonishing—you can even see its effect in age-adjusted cancer mortality overall.

  • Annals corrects NutriRECS red, processed meat papers to reflect industry-related funding from Texas A&M AgriLife

    The Annals of Internal Medicine has published a correction to the controversial meta-analyses of health outcomes related to consumption of red and processed meat—announcing that the lead author of the journal’s “new guidelines,” Bradley Johnston, didn’t disclose funding from AgriLife Research.

  • Top 25 Stories of 2019

    We went through our analytics: here is what your colleagues in oncology read in 2019.

  • NCI advisors approve seven concepts at joint NCAB/BSA meeting

    The NCI Board of Scientific Advisors has approved seven new and reissue concepts—Requests for Applications, Requests for Proposals, and PARs.

  • In Brief

    • Thomas J. Lynch Jr. named president and director of Fred Hutch
    • Aaron Crane named executive VP of Seattle Cancer Care Alliance
    • Bhramar Mukherjee, Christopher Friese named associate directors at Rogel Cancer Center
    • Christopher Ballas appointed SVP at Innovative Cellular Therapeutics
  • Funding Opportunities

    ALK Positive and LUNGevity issue RFA for 2020 ALK-positive Lung Cancer Research Award Program

    ALK Positive/LUNGevity is requesting applications for the 2020 ALK-positive Lung Cancer Research Award. Letters of intent are due Feb. 14.

  • TCCL Logo

  • Trials & Tribulations

    Advancing the science of cancer in Latinos

    Having cancer as a Latino in the United States has important implications potentially related to risk of carcinogenesis, knowledge of cancer prevention, access to cancer screening, therapy timing and choices, and access to good supportive/palliative or survivorship care.

  • Clinical Roundup

    • Keytruda shows mixed results in late-stage lung cancer study
    • Breast density notification laws not effective for all women
    • Researchers surprised by high levels of alcohol consumption among cancer survivors
    • Surgery may add months or years of survival for adults with high-grade gliomas
  • Drugs & Targets

    • FDA approves Keytruda for BCG-unresponsive, high-risk non-muscle invasive bladder cancer
    • FDA approves Ayvakit for unresectable or metastatic PDGFRA Exon 18 mutant gastrointestinal stromal tumor
    • Enfortumab vedotin gets FDA accelerated approval for advanced urothelial or bladder cancer
    • FDA grants IceCure clearance for expanded indications of cryoablation technology and regulatory approval of MultiSense system
    • Canada approves treatment for relapsed/refractory chronic lymphocytic leukemia as part of Project Orbis collaboration
Issue 1 - Jan 3, 2020
  • FDA guidance restricts e-cigarette flavors, leaving tobacco and menthol on the market

    FDA Jan. 2 issued a final guidance that will restrict the sale of e-cigarette flavors most popular with minors.

  • Guest Editorial

    FDA e-cigarette flavoring ban leaves a bad taste


    The ink hadn’t dried on the headline of the lead story in the Dec. 29 issue of The New York Times when on Jan. 2 HHS Secretary Alex Azar and newly arrived FDA Commissioner Stephen M. Hahn made the following announcement:

  • Pazdur on the challenge of approving drugs for small indications

    ODAC recommends approval for tazemetostat in rare sarcoma, sNDAs for Lynparza, Keytruda

    The FDA Oncologic Drugs Advisory Committee in a session Dec. 17 and 18 considered three applications that were arranged thematically, to show how the agency is approaching indications where the number of patients is small and the disease catastrophic.

  • Moffitt CEO Alan List, director Thomas Sellers resign over conflicts of interests involving China

    Thomas Sellers, director of Moffitt Cancer Center, and Alan List, president and CEO of the center, stepped down Dec. 18 after an internal review revealed that they violated “conflict of interest rules through their work in China,” cancer center officials said.

  • Trump approves $212.5M increase to improve NCI success rates; FY20 spending bills provide new funding for childhood cancer, raise tobacco-purchase age to 21

    President Donald Trump signed $1.4 trillion in spending bills Dec. 20 that includes a $212.5 million increase for NCI to cope with an avalanche of grant applications and improve the institute’s declining success rates.

  • Fox Chase acquired by Jefferson in definitive agreement with Temple

    Thomas Jefferson University and Temple University Dec. 18 entered into a binding definitive agreement for Jefferson’s acquisition of Fox Chase Cancer Center and Temple’s Bone Marrow Transplant Program.

  • In Brief

    • HHS proposes plan to import cheaper drugs from Canada
    • Vokes elected ASCO president for 2021-22
    • Hahn sworn in as FDA commissioner
    • Fred Hutch receives $13M SPORE for immunotherapy, lung cancer research
    • Mt. Sinai receives $10M in NIH funding for brain tumor research
    • Ten oncology practices in underserved communities receive ASCO funding to participate in quality improvement programs
    • PharmaMar and Jazz Pharmaceuticals sign license agreement for lurbinectedin in U.S.
  • TCCL Logo

  • Clinical Roundup

    • NCCN pediatric cancer guidelines focus on improving long-term outcomes worldwide
    • SWOG study focuses on impact of vitamin and antioxidant supplement use in cancer patients
    • DREAMM-2 demonstrates meaningful ORR with belantamab mafodotin in multiple myeloma
  • Drugs & Targets

    • FDA approves Lynparza as first-line maintenance treatment of germline BRCA-mutated metastatic pancreatic cancer
    • FDA approves Xtandi for metastatic castration-sensitive prostate indication
    • FDA approves treatment for patients with HER2-positive breast cancer who have progressed on available therapies
    • FDA grants accelerated approval to enfortumab vedotin-ejfv for metastatic urothelial cancer
    • FDA grants Avatrombopag Orphan Drug Designation for chemotherapy-induced thrombocytopenia
    • Karyopharm submits NDA for Xpovio for relapsed or refractory diffuse large B-cell lymphoma
    • Amgen and Allergan submit BLA for biosimilar candidate to Rituxan
    • China approves Zejula as maintenance therapy for recurrent ovarian cancer